April 1, 2012 (Vol. 32, No. 7)

Silence Therapeutics promoted Anthony David Sedgwick, Ph.D., to CEO from CBO. Dr. Sedgwick has worked at Silence since September 2011. Prior to that, he was CEO at Novacta and chairman of Plastid. He has also held the position of CEO at Daniolabs and Cambridge Biotechnology.

Anthony David Sedgwick, Ph.D.

PerkinElmer elected Peter Barrett to its board of directors…C3 Jian appointed Duane A. Morris to vp, production and facilities…Genomic Health appointed Julian Baker to lead independent director…Proteros biostructures appointed Klaus Hinterding, Ph.D., as CSO and member of the management board.

Acorda Therapeutics named Jane Wasman, J.D., chief, strategic development. Wasman joined Acorda in 2004 as evp, general counsel and corporate secretary. Before that, she held several leadership positions at Schering-Plough, including staff vp and associate general counsel.

Jane Wasman, J.D.

Wolfgang Oster, M.D., Ph.D., joined Formula Pharmaceuticals as chairman of the board of directors…Stefan Grote joined Gerresheimer’s management board…Unigene Laboratories promoted Gregory T. Mayes to the position of CBO and appointed Jane Pepper, Ph.D., to senior director, business development…PaxVax appointed Nima Farzan as evp and COO, Thomas P. Monath, M.D., as CTO, and Jonathan F. Smith, Ph.D., as evp and CSO.

Permeon Biologics appointed Katherine S. Bowdish, Ph.D., as president and CSO. She is also joining Permeon’s board of directors. Dr. Bowdish was co-founder, president, and CEO of Anaphore. She also founded the firm Prolifaron and served as president of Alexion Antibody Technologies.

Katherine S. Bowdish, Ph.D.

InterMune appointed Jonathan A. Leff, M.D., as evp, R&D…Relypsa hired Lance Berman, M.D., as svp, commercial strategy & medical affairs…Anagnotics added Jörg Hoheisel, Ph.D.Christian Gabriel, M.D.Harald Kessler, M.D., and Klaus M. Weinberger, Ph.D., to its advisory council…Oxford Immunotec appointed Richard Alteri as CFO…Pacific Biosciences promoted Terry Pizzie to vp, global sales…Jorge Garces, Ph.D., joined GenMark Diagnostics as svp, R&D.

Exact Sciences promoted Maneesh K. Arora to COO. Arora had been Exact’s svp and CFO since joining the firm in March 2009. Before that, he had been svp and CFO of Third Wave Technologies, where he started as director of strategy in January 2003.

Maneesh K. Arora

Oxitec appointed Christopher Richards, Ph.D., as nonexecutive chairman…Glenn McGee, Ph.D., joined Celltex Therapeutics as president, ethics and strategic initiatives…Hospira named Zena G. Kaufman svp, quality; Matt Stober cvp, U.S. pharma operations; Shane Ernst vp, quality, Rocky Mountains; Marty Nealey vp, operations and plant manager, Rocky Mountains; Andrew Knudten vp, operations and plant manager, McPherson; and Thomas Templeman, Ph.D., vp, pharma operations excellence.

TAP Biosystems appointed Cathy Maloney as sales director. Maloney previously held several sales management positions, including senior director of North American sales, at Molecular Devices, where she worked for 15 years. Prior to that, she held a technical sales position at Waters.

Cathy Maloney

Trovagene named Charlie Rodi, Ph.D., vp and CTO and Stephen Zaniboni CFO…Allena Pharmaceuticals appointed Gino Santini to its board of directors…Amgen named Michael Severino, M.D., svp, global development and corporate CMO.

Lucy Lu, M.D., is now evp and CFO at Coronado Biosciences. Dr. Lu was most recently a senior biotechnology analyst at Citigroup Investment Research. She has also worked at First Albany Capital as vp and principal, and at Lehman Brothers as associate of healthcare investment banking.

Lucy Lu, M.D.

Lycera added Michael Steinmetz, Ph.D., to its board of directors and appointed Steven Gillis, Ph.D., as the board’s chairman…Cellerant Therapeutics appointed Lowell E. Sears to its board of directors.

Previous articleReport Urges EU Nations to Boost R&D Through Tax, Regulatory Policies
Next articleIngenuity, Life Tech Introduce Solution for Real-Time PCR Gene-Expression Analysis